Previous close | 2.3600 |
Open | 2.3760 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.3760 - 2.3760 |
52-week range | 2.3000 - 2.9900 |
Volume | |
Avg. volume | 5,596 |
Market cap | 14.833B |
Beta (5Y monthly) | 0.52 |
PE ratio (TTM) | 9.90 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.13 (5.29%) |
Ex-dividend date | 29 Apr 2024 |
1y target est | N/A |
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.